Medpace Holdings, Inc. is a scientifically driven, global, full-service clinical contract research organization (CRO) providing phase I-IV clinical development services to the biotechnology, pharmaceutical and medical device industries. The Company partners with pharmaceutical, biotechnology, and medical device companies in the development and execution of clinical trials. The Company’s drug development services focus on full-service Phase I-IV clinical development services and include development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support. The Company also provides bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. The Company’s operations are principally based in North America, Europe, and Asia.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 34.17% year-on-year.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 2.53B.
Fairly Valued
The company’s latest PE is 32.96, at a medium 3-year percentile range.
Institutional Selling
The latest institutional holdings are 24.53M shares, decreasing 9.12% quarter-over-quarter.
Held by John Hussman
Star Investor John Hussman holds 7.08K shares of this stock.